ArticleProceedings. Biological sciences2006
Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges?
Article in Proceedings. Biological sciences, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 65 citations in OpenAlex.
- Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling.BMC public health · 2009Trial
- Serologic evidence of mpox virus exposure among people living with human immunodeficiency virus in Thailand predating clinical recognition during the 2022 outbreak.IJID regions · 2026Article
- Article
- Barriers and facilitators to adherence for antiretroviral therapy: the perspectives of patients from a wellness center in the Mpumalanga Province, South Africa.African health sciences · 2022Article
- Acceptability of and Willingness to Take Digital Pills by Patients, the Public, and Health Care Professionals: Qualitative Content Analysis of a Large Online Survey.Journal of medical Internet research · 2022Article
- Review
- Option B plus antiretroviral therapy adherence and associated factors among HIV positive pregnant women in Southern Ethiopia.BMC pregnancy and childbirth · 2019Article
- Acceptable medication non-adherence: A crowdsourcing study among French physicians for commonly prescribed medications.PloS one · 2018Article
- Mass drug administration: the importance of synchrony.Mathematical medicine and biology : a journal of the IMA · 2017Article
- Personalized life expectancy and treatment benefit index of antiretroviral therapy.Theoretical biology & medical modelling · 2017Article
- Of mice and monkeys: can animal models be utilized to study neurological consequences of pediatric HIV-1 infection?ACS chemical neuroscience · 2015Review
- Modeling antiretroviral drug responses for HIV-1 infected patients using differential equation models.Advanced drug delivery reviews · 2013Review
- Antiretroviral dynamics determines HIV evolution and predicts therapy outcome.Nature medicine · 2012Article
- Adherence to combination prophylaxis for prevention of mother-to-child-transmission of HIV in Tanzania.PloS one · 2011Article
- Measuring adherence to antiretroviral treatment in resource-poor settings: the feasibility of collecting routine data for key indicators.BMC health services research · 2010Article
- Modelling imperfect adherence to HIV induction therapy.BMC infectious diseases · 2010Article
- Modeling HIV persistence, the latent reservoir, and viral blips.Journal of theoretical biology · 2009Review
- Modeling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibility.Journal of theoretical biology · 2007Article
- Patient and regimen characteristics associated with self-reported nonadherence to antiretroviral therapy.PloS one · 2007Article
- Improving estimates of the basic reproductive ratio: using both the mean and the dispersal of transition times.Theoretical population biology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The question of determining how many doses may be skipped before HIV treatment response is adversely affected by the emergence of drug-resistance is addressed. Impulsive differential equations are used to develop a prescription to minimize the emergence of drug-resistance for protease-sparing regimens. A threshold for the maximal number of missable doses is determined. If the number of missed doses is below this threshold, then resistance levels are negligible and dissipate quickly, assuming perfect adherence subsequently. If the number of missed doses exceeds this threshold, even for 24h, resistance levels are extremely high and will not dissipate for weeks, even assuming perfect adherence subsequently. After this interruption, the minimum number of successive doses that should be taken is determined. Estimates are provided for all protease-sparing drugs approved by the US Food and Drug Administration. Estimates for the basic reproductive ratios for the wild-type and mutant strains of the virus are also calculated, for a long-term average fractional degree of adherence. There are regions within this fraction of adherence where the outcome is not predictable and may depend on a patient's entire history of drug-taking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.